

Cartonless packaging for first-line antiretroviral (ARV) treatments

Space-saving packaging innovations for first-line ARVs, including TLE, TLD and TEE, are enabling significant cost savings and efficiencies for Global Fund Principal Recipients.

The Global Fund's Sourcing Department aims to achieve the best value for money for grant procurements. Through strategic sourcing, we encourage manufacturers to reduce the cost of ARVs by offering innovative shrink wrapping to replace traditional cardboard mono-cartons.

Cartonless packaging options for TLE600, TLE400, TLD and TEE* are available on wambo.org, the Global Fund's online procurement platform.

Many countries, including Zambia, Malawi, Nigeria and DRC, have made the switch and the Global Fund is transitioning all first-line ARVs to cartonless packaging in 2019. The significant financial savings can be reinvested in HIV programs to provide life-saving treatments for additional patients.

Will your country program order TLE, TLD or TEE?

- ▶ Determine the quantity of treatments needed. The Global Fund can provide an estimate of financial and freight savings based on anticipated demand.
- ▶ Place your order in wambo.org, and make sure to choose the 'cartonless' product option.
- ▶ Suppliers are actively pursuing registration variation notifications for cartonless packaging. Principal Recipients are encouraged to place orders with cartonless packaging.

400,000 ADDITIONAL PATIENTS

Switching to cartonless packaging reduces the cost of annual treatment by \$1.80 per patient, resulting in \$29 million of savings across all Global Fund grants. This could increase access to life-saving ARV treatment for an additional 400,000 patients.


1/3 STORAGE SPACE REDUCTION

Cartonless packaging generates savings throughout the supply chain, including reducing total shipment volume and required storage space on average by 33%, versus traditional ARV packaging.

5 MILLION KILOGRAMS PAPER SAVED

Eliminating packaging material reduces our carbon footprint. When all Global Fund-financed first line ARVs are purchased with the optimal packaging, in addition to paper savings, 900 tons of wood will be saved.

*Efavirenz/Lamivudine/Tenofovir 600/300/300mg;
Efavirenz/Lamivudine/Tenofovir 400/300/300mg;
Dolutegravir/Lamivudine/Tenofovir 50/300/300mg;
Efavirenz/Emtricitabine/Tenofovir 600/200mg/300mg



Financial savings and supply chain efficiencies achieved in Zambia, July 2018

MOH Zambia and the Global Fund worked together to place an order for four million packs of TLE400 in wambo.org – the first order of cartonless packaging procured with Global Fund financing.

- ▶ This single order generated financial savings of US\$766,000 from unit cost reduction and freight savings - enough to provide annual ARV treatment for an additional 9,000 patients
- ▶ Total volume reduced by 51%, lowered storage space requirements
- ▶ Estimated 100 tons of paper and 17 tons of wood saved

What is cartonless packaging?

Shrink wrapped bottles are packed together in shippers, strapped on shipping pallets and loaded in 20 or 40 foot containers. Eliminating the traditional cardboard mono-carton means that more bottles can be packed in each shipper, reducing the total volume of goods on average by more than one third.

Dispensing is simpler and more efficient at the patient level. The cardboard mono-cartons can arrive looking crushed and damaged from transit and are discarded by health clinic workers. Shrink wrapping ensures the products arrive secure and intact, and results in less waste.



TLE-400, shrink wrapped in shipper cartons.

Cartonless packaging also adds value throughout the supply chain. Reduced freight volumes improve transportation requirements and optimize valuable storage space in warehouses, distribution centers and health clinics.

The Global Fund is working with manufacturers to encourage rapid availability of cartonless packaging for first-line ARV treatments in all countries. Principal Recipients are encouraged to reach out to their Global Fund Sourcing Department focal points with any questions about how switching to cartonless packaging for first-line ARV treatments can benefit HIV programs.